Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer

Key Points

• Toxicities from PI3K/AKT/mTOR inhibitors significantly impact patient quality of life and treatment adherence.
• Common adverse effects include gastrointestinal disturbances, rash, and metabolic changes.
• Management strategies involve supportive care and dose adjustments to mitigate these toxicities.
• Thorough understanding of these side effects can enhance treatment outcomes and patient satisfaction.